XomaZyme-Mel

Drug Profile

XomaZyme-Mel

Alternative Names: antimelanoma antibody-ricin A conjugate

Latest Information Update: 29 Jun 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Class Antibodies; Antineoplastics; Immunotoxins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 29 Jun 1999 Discontinued-II for Malignant melanoma in USA (IV-infusion)
  • 29 May 1997 No-Development-Reported for Malignant melanoma in USA (IV-infusion)
  • 29 May 1995 Phase-II clinical trials for Malignant melanoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top